This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Compound 5 showed remarkable functional selectivity toward the hMC1R receptor.
Why it matters
Improving selectivity of receptor agonists can lead to better therapeutic options with fewer side effects. This research contributes to the development of targeted treatments for conditions influenced by melanocortin receptors.
How the study worked
The study utilized a Chemical Linkage of Peptide onto Scaffolds strategy to modify melanotan II and assessed binding affinities through molecular dynamics simulations.
What this study cannot tell us
The study primarily focuses on in vitro findings, which may not fully translate to in vivo results or human applications.
Read the original research
CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.
Journal of medicinal chemistry, 65(5), 4007-4017
Citation
Tomassi, Stefano; Dimmito, Marilisa Pia; Cai, Minying; D'Aniello, Antonia; Del Bene, Alessandra; Messere, Anna; Liu, Zekun; Zhu, Tingyi; Hruby, Victor J; Stefanucci, Azzurra; Cosconati, Sandro; Mollica, Adriano; Di Maro, Salvatore. (2022). CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.. Journal of medicinal chemistry, 65(5), 4007-4017. https://doi.org/10.1021/acs.jmedchem.1c01848